Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2021 Feb:101:106246.
doi: 10.1016/j.cct.2020.106246. Epub 2020 Dec 11.

A randomized, open-label, pragmatic study to assess reliever-triggered inhaled corticosteroid in African American/Black and Hispanic/Latinx adults with asthma: Design and methods of the PREPARE trial

Affiliations
Randomized Controlled Trial

A randomized, open-label, pragmatic study to assess reliever-triggered inhaled corticosteroid in African American/Black and Hispanic/Latinx adults with asthma: Design and methods of the PREPARE trial

Elliot Israel et al. Contemp Clin Trials. 2021 Feb.

Abstract

Asthma prevalence, morbidity, and mortality disproportionately impact African American/Black (AA/B) and Hispanic/Latinx (H/L) communities. Adherence to daily inhaled corticosteroid (ICS), recommended by asthma guidelines in all but the mildest cases of asthma, is generally poor. As-needed ICS has shown promise as a patient-empowering asthma management strategy, but it has not been rigorously studied in AA/B or H/L patients or in a real-world setting. Design and Aim The PeRson EmPowered Asthma RElief (PREPARE) Study is a randomized, open-label, pragmatic study which aims to assess whether a patient-guided, reliever-triggered ICS strategy called PARTICS (Patient-Activated Reliever-Triggered Inhaled CorticoSteroid) can improve asthma outcomes in AA/B and H/L adult patient populations. In designing and implementing the study, the PREPARE research team has relied heavily on advice from AA/B and H/L Patient Partners and other stakeholders. Methods PREPARE is enrolling 1200 adult participants (600 AA/Bs, 600H/Ls) with asthma. Participants are randomized to PARTICS + Usual Care (intervention) versus Usual Care (control). Following a single in-person enrollment visit, participants complete monthly questionnaires for 15 months. The primary endpoint is annualized asthma exacerbation rate. Secondary endpoints include asthma control; preference-based quality of life; and days lost from work, school, or usual activities. Discussion The PREPARE study features a pragmatic design allowing for the real-world assessment of a patient-centered, reliever-triggered ICS strategy in AA/B and H/L patients. Outcomes of this study have the potential to offer powerful evidence supporting PARTICS as an effective asthma management strategy in patient populations that suffer disproportionately from asthma morbidity and mortality.

Keywords: African American; Asthma; Exacerbations; Hispanic; Patient-centered; Pragmatic trial.

PubMed Disclaimer

Figures

Fig. 1.
Fig. 1.
PREPARE study design. AA/B: African American/Black; H/L: Hispanic/Latinx.
Fig. 2.
Fig. 2.
PREPARE PRECIS diagram.

References

    1. Centers for Disease Control and Prevention, Most Recent National Asthma Data. https://www.cdc.gov/asthma/most_recent_national_asthma_data.htm, 2018. accessed 15 June 2020.
    1. Nurmagambetov T, Kuwahara R, Garbe P, The economic burden of asthma in the United States, 2008–2013, Ann. Am. Thorac. Soc 15 (2018) 348–356, 10.1513/AnnalsATS.201703-259OC. - DOI - PubMed
    1. Reddel HK, Tyler DR, Bateman ED, et al., An official American Thoracic Society/European Respiratory Society statement: asthma control and exacerbations, Am. J. Respir. Crit. Care Med 180 (2009) 59–99, 10.1164/rccm.200801-060ST. - DOI - PubMed
    1. Lane S, Molina J, Plusa T, An international observational prospective study to determine the cost of asthma exacerbations (COAX), Respir. Med 100 (2006) 434–450, 10.1016/j.rmed.2005.06.012. - DOI - PubMed
    1. Gold DR, Wright R, Population disparities in asthma, Annu. Rev. Public Health 26 (2005) 89–113, 10.1146/annurev.publhealth.26.021304.144528. - DOI - PubMed

Publication types

Substances